Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers
On April 27, 2021, Jay Scollins notified Helix Acquisition Corp. (the "Company")
of his decision to resign from his position as Chief Financial Officer,
effective April 30, 2021. Mr. Scollins' decision to resign is not related to any
disagreement with the Company or its auditors on any matter relating to the
Company's operations, policies or practices.
The board of directors of the Company has appointed Andrew Phillips as Chief
Financial Officer, effective April 30, 2021. Dr. Phillips, 50, is a Managing
Director at Cormorant Asset Management, LP, where he has served since 2020.
Prior to joining Cormorant Asset Management, LP, Dr. Phillips served at C4
Therapeutics, Inc., a company pioneering targeted protein degradation medicines,
from 2016, most recently as the President and Chief Executive Officer from 2018
to 2020. Prior to joining C4 Therapeutics, Inc., Dr. Phillips was Senior
Director, Center for Development of Therapeutics at the Broad Institute of MIT
and Harvard, where he led overall therapeutic efforts and provided strategic
leadership for a number of major partnerships from 2014 to 2016. Dr. Phillips
was a Full Professor of Chemistry at Yale University from 2010 to 2015 and a
Full Professor of Chemistry and Biochemistry at the University of Colorado from
2001 to 2010. Dr. Phillips holds Ph.D. and B.Sc. Hons. degrees in Biochemistry
and Chemistry from the University of Canterbury (Christchurch, New Zealand).
There are no family relationships between Dr. Phillips and any director or
executive officer of the Company, and there are no related party transactions
between the Company and Dr. Phillips that would require disclosure under Item
404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended.
1© Edgar Online, source Glimpses
HELX ACQU